FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APP	OIVID APPROVAL									
OMB Number:	3235-02									

Cricck this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	rden								
hours ner response:	0.5								

1. Name and Address of Reporting Person* <u>LEVIN ALAN G</u>				2. Issuer Name and Ticker or Trading Symbol  Diffusion Pharmaceuticals Inc. [ DFFN ]										ck all applic	,		son(s) to Iss 10% O			
(Last) 1317 CA	`	irst) /ENUE, SUITE	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/13/2019										Officer (give title below)		Other ( below)	specify	
(Street) CHARLOTTESVILLE VA 22902 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year) 07/19/2019								Line)	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	ole I - Nor	ı-Deriv	ative	e Se	curities	s Ac	quired,	Dis	posed c	of, or B	enef	icially	/ Owned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D							2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.				4 and Securiti Benefici Owned		s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	Amount			(A) (D)	or F	Price	Reported Transact (Instr. 3 a	tion(s)			(111501.4)				
Common Stock															1,0	1,654		D		
		-	Table II -								osed of, onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	ransa Code (I		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea		•	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nui of	nount mber ares						
Stock Option (Right to	\$3.15	06/13/2019			A		19,200		(1)	C	06/13/2029	Commo	<sup>1</sup> 19	,200	\$0	19,20	0	D		

## **Explanation of Responses:**

1. The shares underlying the options vest in equal parts on the last calendar day of each month until fully vested on May 31, 2020.

## Remarks:

This amendment is being filed solely to correct an error in the reported number of Derivative Securities awarded in the original filing.

/s/ David G. Kalergis, attorneyin-fact for Alan G. Levin

08/01/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.